All Clinical Trials

A listing of 23144 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome

NCT00001727

Recruiting

Polyostotic fibrous dysplasia (PFD) is a sporadic disorder which affects multiple sites in the skeleton. The bone at these sites is rapidly resorbed and replaced by abnormal fibrous tissue or mechanically abnormal bone. PFD may occur alone or as part of the McCune-Albright Syndrome (MAS), a syndrome originally defined by the triad of PFD, cafe-au-lait pigmentation of the skin, and precocious puberty. The bony lesions are frequently disfiguring, disabling and painful, and depending on the location of the lesion, can cause significant morbidity. Lesions in weight-bearing bones can lead to disabling fractures, while lesions in the skull can lead to compression of vital structures such as cranial nerves. The natural history of this disease is poorly described and there are no clearly defined systemic therapies for the bone disease. This is a data collection and specimen acquisition protocol. The purpose of the study is to define the natural history of the disease by following PFD/MAS subjects over time and by using in vitro experimentation with samples/tissue from subjects with the disease. Study Objectives 1. Primary Objective Define the natural history of disease by gaining clinical and basic information about PFD/MAS by following subjects clinically and using in vitro experimentation with tissue from subjects with the disease. 2. Secondary Objective Refer eligible subjects for enrollment into other appropriate research protocols, if any are currently active. Study Population The study population will include: 1. Subjects with known or suspected Polyostotic Fibrous Dysplasia (PFD) or in combination with McCune-Albright Syndrome (MAS) 2. Subjects who meet eligibility criteria will be accepted regardless of gender, race, or ethnicity Design This study is an observational/natural history study of PFD/MAS. Outcome Measures Primary 1. Successfully enroll subjects with PFD or MAS for the collection, evaluation and analysis of data obtained from clinical visits. 2. Obtain onsite and offsite research tissue (waste tissue) from patients with PFD/MAS that are enrolled onto this study or from individuals with PFD/MAS that are offsite and willing to donate waste tissue to NIH. Research tissue will be used with existing primary cell culture technology (ongoing in our laboratories) to: * understand the basic bone biology of the pathologic cell (or cells) involved in the lesions of PFD/MAS * determine the presence or absence of mutated cells at "uninvolved sites" to formulate better strategies of predicting the initiation of new lesions, the natural history of lesion progression and/or response to therapy * understand osteogenic differentiation, in particular, the role of G(s)alpha in these lesions, which will be transferable to our understanding of bone biology in general * understand the pathophysiology of FD and/or endocrine lesions * develop better methods of identifying and expanding unaffected bone cells from patients with PFD in an effort to create better grafting material(s) 3. Identify and predict clinical and biological behavior of fibrous dysplastic bone lesions based on: * stability, rate of growth, rate of change, progression and regression, and development of new lesions * differences between cranial, axial and appendicular lesions 4. Define the natural history of the multiple endocrinopathies associated with MAS and the response to standard of care medications 5. Define clinical and biological aspects of the disease not previously identified 6. Generate future research studies related to PFD alone or in combination with MAS Secondary 1) Successfully enroll eligible subjects into active research protocols applicable to the FD/MAS population. Read Less

Gender:

ALL

Ages:

Between 1 day and 100 years

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: McCune-Albright Syndrome

Learn More ›

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352

Recruiting

This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will: * Fill out one or two questionnaires about their personal and family medical history. * Provide written consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with melanomas, tumors, cancer, or other related illnesses for whom they are the next-of-kin or legally authorized representative. * Donate a blood or cheek cell sample to be used for genetic studies. (The blood sample is collected through a needle in an arm vein. The cheek cell sample is obtained either by gently brushing the inside of the mouth with a soft brush or by swishing a tablespoon of mouthwash and then spitting it into a container.) * Undergo a skin biopsy (removal of a small piece of skin tissue) for genetic study. For this procedure, the area of skin to be removed is numbed with a local anesthetic and a 1/4-inch piece of skin is excised with a cookie cutter-like instrument. The wound is then covered with a band-aid. Participants may be asked to travel to the NIH Clinical Center for evaluation, including a medical history, physical examination, and some of the following procedures: * Full body skin examination to evaluate the type and number of moles and document any evidence of sun damage to the skin. The examination involves all the skin from the scalp to the bottoms of the feet. After the examination, a medical photographer will photograph the skin, with close-ups of skin lesions marked by the examiner. If there are parts of the skin the participant does not want examined or photographed, he or she can tell the examiner. * Blood draw of about 120 milliliters (4 ounces) or less * Skin biopsy * Cheek cell sample * X-rays, ultrasound and magnetic resonance imaging (MRI) studies to detect tumors or changes in tumors or other types of changes in specific tissues. MRI is a diagnostic test that uses strong magnetic fields and radiowaves to examine body tissues. The subject lies on a table that is moved into a large tunnel-like machine (the scanner) for about 45 minutes to 1 hour. When the tests are finished, a doctor will discuss the results with the participant and the need, if any, for clinical follow-up.... Read Less

Gender:

ALL

Ages:

Between 4 weeks and 99 years

Trial Updated:

05/02/2025

Locations: National Cancer Institute (NCI), Bethesda, Maryland +1 locations

Conditions: Melanoma, Dysplastic Nevus Syndrome

Learn More ›

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

NCT00271622

Recruiting

The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH....

Gender:

ALL

Ages:

6 weeks and above

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neurologic Disorders, Autism, Neurodegenerative Disease, Neurobehavioral Manifestation

Learn More ›

Imaging Techniques in MRI

NCT01130545

Recruiting

Background: - Magnetic resonance imaging (MRI) scans must be performed according to specified sets of parameters that provide optimal images of each organ and each area of the body. These scanning parameters are often specific to the institution or organization at which they are employed, and may also depend on the manufacturer of the MRI scanning equipment. Because MRI scanning equipment is always being updated and upgraded, researchers are interested in developing new and optimized scanning p... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Cardiac Risk Factors, Healthy, Healthy Volunteers

Learn More ›

New Heart Imaging Techniques to Evaluate Possible Heart Disease

NCT01399385

Recruiting

Background: - Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness. This information may help diagnose and treat heart disease and other conditions that lead to heart attacks. Better MRI methods are needed to improve heart disease diagnosis, especially by avoiding the use of radiation. Researchers are testing new techniques to improve the qualit... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Healthy, Obesity, Diabetes, Healthy Volunteers, Atherosclerosis

Learn More ›

Rapid Autopsy and Procurement of Cancer Tissue

NCT01851395

Recruiting

Background: - Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease. Some agree to donate their bodies to cancer research that may help the medical community better understand these diseases. Studies of cancer tumor tissue obtained soon after death may be used to answer questions about the origins, progression, and treatment of cancer. Researchers want to conduct... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers, Lung Cancers

Learn More ›

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

NCT02594202

Recruiting

Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any changes in cells and genes. These changes might lead to the development and progression of prostate cancer. Researchers think the study could lead to new treatments. Objective: To understand the changes in cells and genes that lead to the development and progression of prostate can... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Prostate Cancer

Learn More ›

Vascular Disease Discovery Protocol

NCT03538639

Recruiting

Background: Some genetic diseases put increase the risk of heart and blood diseases, which are the number one cause of death and disability in the U.S. Researchers want to study diseases of the heart and/or blood vessels. They want to collect data and specimens from affected people, their family members, and healthy people. Objective: To study diseases of the heart and/or blood vessels. Eligibility: People age 2 and older who may have genetic disease affecting the heart and/or blood vessels... Read More

Gender:

ALL

Ages:

Between 2 years and 100 years

Trial Updated:

05/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Vascular Dysfunction, Genetic Mutations, Genetic Predisposition

Learn More ›

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

NCT04323046

Recruiting

This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

05/02/2025

Locations: University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama +19 locations

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma

Learn More ›

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Recruiting

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from ge... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +78 locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Augusta University Medical Center, Augusta, Georgia

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho

Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho

Carle at The Riverfront, Danville, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Carle Cancer Center, Urbana, Illinois

IU Health North Hospital, Carmel, Indiana

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky

UofL Health Medical Center Northeast, Louisville, Kentucky

Washington University School of Medicine, Saint Louis, Missouri

Community Hospital of Anaconda, Anaconda, Montana

Billings Clinic Cancer Center, Billings, Montana

Saint Vincent Frontier Cancer Center, Billings, Montana

Intermountain Health West End Clinic, Billings, Montana

Bozeman Health Deaconess Hospital, Bozeman, Montana

Benefis Sletten Cancer Institute, Great Falls, Montana

Community Medical Center, Missoula, Montana

Nebraska Methodist Hospital, Omaha, Nebraska

University of New Mexico Cancer Center, Albuquerque, New Mexico

Roswell Park Cancer Institute, Buffalo, New York

University of Rochester, Rochester, New York

Duke University Medical Center, Durham, North Carolina

Duke Women's Cancer Care Raleigh, Raleigh, North Carolina

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania

UPMC Hillman Cancer Center at Butler Health System, Butler, Pennsylvania

UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township, Pennsylvania

UPMC Hillman Cancer Center Erie, Erie, Pennsylvania

UPMC Cancer Center at UPMC Horizon, Farrell, Pennsylvania

UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania

IRMC Cancer Center, Indiana, Pennsylvania

UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania

UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion, Mechanicsburg, Pennsylvania

UPMC Hillman Cancer Center - Monroeville, Monroeville, Pennsylvania

UPMC Hillman Cancer Center in Coraopolis, Moon, Pennsylvania

UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant, Pennsylvania

Arnold Palmer Cancer Center Medical Oncology Norwin, N. Huntingdon, Pennsylvania

UPMC Cancer Center-Natrona Heights, Natrona Heights, Pennsylvania

UPMC Hillman Cancer Center - New Castle, New Castle, Pennsylvania

NRG Oncology, Philadelphia, Pennsylvania

UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania

UPMC-Saint Margaret, Pittsburgh, Pennsylvania

UPMC-Mercy Hospital, Pittsburgh, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

UPMC-Passavant Hospital, Pittsburgh, Pennsylvania

UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania

UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania

UPMC Cancer Center-Washington, Washington, Pennsylvania

UPMC West Mifflin-Cancer Center Jefferson, West Mifflin, Pennsylvania

Women and Infants Hospital, Providence, Rhode Island

Parkland Memorial Hospital, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas

UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma

Learn More ›

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

NCT05538897

Recruiting

This phase Ib/II trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Megestrol acetate lowers the amount of estrogen and also blocks the use of estrogen made... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: Banner University Medical Center - Tucson, Tucson, Arizona +149 locations

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arizona Cancer Center-North Campus, Tucson, Arizona

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas

Highlands Oncology Group - Rogers, Rogers, Arkansas

Highlands Oncology Group, Springdale, Arkansas

University of California Davis Comprehensive Cancer Center, Sacramento, California

UCHealth University of Colorado Hospital, Aurora, Colorado

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Sarasota Memorial Hospital-Venice, N. Venice, Florida

Florida Cancer Specialists - Sarasota Downtown, Sarasota, Florida

First Physicians Group-Sarasota, Sarasota, Florida

Sarasota Memorial Hospital, Sarasota, Florida

Florida Cancer Specialists - Venice Pinebrook, Venice, Florida

Augusta University Medical Center, Augusta, Georgia

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho

Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho

Northwestern University, Chicago, Illinois

Carle at The Riverfront, Danville, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Crossroads Cancer Center, Effingham, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois

Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Cancer Care Center of O'Fallon, O'Fallon, Illinois

Northwestern Medicine Orland Park, Orland Park, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Springfield Memorial Hospital, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

IU Health North Hospital, Carmel, Indiana

Parkview Regional Medical Center, Fort Wayne, Indiana

Goshen Center for Cancer Care, Goshen, Indiana

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

Memorial Hospital of South Bend, South Bend, Indiana

UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa

Iowa Methodist Medical Center, Des Moines, Iowa

UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

Harold Alfond Center for Cancer Care, Augusta, Maine

MaineHealth Maine Medical Center- Scarborough, Scarborough, Maine

Walter Reed National Military Medical Center, Bethesda, Maryland

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Bronson Battle Creek, Battle Creek, Michigan

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

West Michigan Cancer Center, Kalamazoo, Michigan

Ascension Borgess Cancer Center, Kalamazoo, Michigan

Trinity Health Muskegon Hospital, Muskegon, Michigan

Corewell Health Lakeland Hospitals - Niles Hospital, Niles, Michigan

Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan

Corewell Health Reed City Hospital, Reed City, Michigan

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center, Saint Joseph, Michigan

Corewell Health Lakeland Hospitals - Saint Joseph Hospital, Saint Joseph, Michigan

Munson Medical Center, Traverse City, Michigan

University of Michigan Health - West, Wyoming, Michigan

Mercy Hospital, Coon Rapids, Minnesota

Fairview Southdale Hospital, Edina, Minnesota

Abbott-Northwestern Hospital, Minneapolis, Minnesota

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

Regions Hospital, Saint Paul, Minnesota

United Hospital, Saint Paul, Minnesota

Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota

MU Health - University Hospital/Ellis Fischel Cancer Center, Columbia, Missouri

MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

Mercy Hospital South, Saint Louis, Missouri

Mercy Hospital Saint Louis, Saint Louis, Missouri

Mercy Hospital Springfield, Springfield, Missouri

Community Hospital of Anaconda, Anaconda, Montana

Billings Clinic Cancer Center, Billings, Montana

Bozeman Health Deaconess Hospital, Bozeman, Montana

Benefis Sletten Cancer Institute, Great Falls, Montana

Community Medical Center, Missoula, Montana

Cooper Hospital University Medical Center, Camden, New Jersey

University of New Mexico Cancer Center, Albuquerque, New Mexico

Montefiore Medical Center-Einstein Campus, Bronx, New York

Montefiore Medical Center-Weiler Hospital, Bronx, New York

Montefiore Medical Center - Moses Campus, Bronx, New York

University of Rochester, Rochester, New York

State University of New York Upstate Medical University, Syracuse, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Atrium Health Cabarrus/LCI-Concord, Concord, North Carolina

Summa Health System - Akron Campus, Akron, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

Upper Valley Medical Center, Troy, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma

Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Jefferson Hospital, Jefferson Hills, Pennsylvania

Forbes Hospital, Monroeville, Pennsylvania

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

West Penn Hospital, Pittsburgh, Pennsylvania

Wexford Health and Wellness Pavilion, Wexford, Pennsylvania

Asplundh Cancer Pavilion, Willow Grove, Pennsylvania

Women and Infants Hospital, Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

Parkland Memorial Hospital, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas

Lyndon Baines Johnson General Hospital, Houston, Texas

M D Anderson Cancer Center, Houston, Texas

Memorial Hermann Texas Medical Center, Houston, Texas

UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

VCU Massey Cancer Center at Stony Point, Richmond, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Carilion Roanoke Memorial Hospital, Roanoke, Virginia

Swedish Cancer Institute-Edmonds, Edmonds, Washington

Swedish Cancer Institute-Issaquah, Issaquah, Washington

Swedish Medical Center-First Hill, Seattle, Washington

West Virginia University Charleston Division, Charleston, West Virginia

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma

Learn More ›

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06004245

Recruiting

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy, and in combination with pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cance... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: City of Hope Cancer Center, Duarte, California +24 locations

Conditions: Advanced Solid Tumors

Learn More ›